title: No influence of body weight on pregnancy rate in patients treated with cetrorelix according to the single- and multiple-dose protocols.
abstract: The question of whether adjustment to body weight is necessary in in-vitro fertilization (IVF) cycles using GnRH antagonists is currently under discussion. Therefore, a data analysis of five prospective studies using either the single- or the multiple-dose antagonist protocol with cetrorelix (Cetrotide) was performed. The influence of stimulation procedure, gonadotrophins and body weight on pregnancy rate was evaluated in a linear logit model. The effect of the stimulation procedure and body weight on the cumulus-oocyte complex (COC) and follicle number was explored in an ANOVA model. Cetrorelix plasma concentrations were tested for any correlation with body weight. Baseline and outcome parameters in different body weight groups (<50 kg, 50-59 kg, 60-69 kg, 70-79 kg, > or =80 kg) were assessed for human menopausal gonadotrophin and recombinant human FSH stimulation separately. Cetrorelix plasma concentrations were correlated with body weight, but no influence of the type of stimulation or body weight on pregnancy rate was found. Body weight did not influence cetrorelix plasma concentrations. In contrast, body weight significantly influenced the number of retrieved COC as well as the number of follicles on the day of human chorionic gonadotrophin administration. Body weight does not influence the outcome of treatment in cetrorelix cycles.
authors.affiliation: Department of Gynecology and Obstetrics, University Clinic, Lübeck, Germany.
authors.forename: J B
authors.initials: JB
authors.lastname: Engel
authors.forename: M
authors.initials: M
authors.lastname: Ludwig
authors.forename: K
authors.initials: K
authors.lastname: Junge
authors.forename: C M
authors.initials: CM
authors.lastname: Howles
authors.forename: K
authors.initials: K
authors.lastname: Diedrich
mesh_terms: D001835:Body Weight; D002452:Cell Count; D005260:Female; D005307:Fertilization in Vitro; D005640:Follicle Stimulating Hormone / Q000627:therapeutic use; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage* / Q000031:analogs & derivatives / Q000037:antagonists & inhibitors / Q000097:blood; D006727:Hormone Antagonists / Q000008:administration & dosage* / Q000097:blood; D006801:Humans; D016014:Linear Models; D008596:Menotropins / Q000627:therapeutic use; D009865:Oocytes; D009994:Osmolar Concentration; D006080:Ovarian Follicle / Q000502:physiology; D010062:Ovulation Induction / Q000379:methods; D011247:Pregnancy; D018873:Pregnancy Rate; D012189:Retrospective Studies; D020858:Tissue and Organ Harvesting; D016896:Treatment Outcome
chemical_list: D006727:Hormone Antagonists; D007987:Gonadotropin-Releasing Hormone; D008596:Menotropins; D005640:Follicle Stimulating Hormone; C062876:cetrorelix